Citation & Authors
Diabetes Res Clin Pract. 2026;236:113267.
ABSTRACT · RESEARCH SUMMARY
Research summary
This Taiwanese National Health Insurance study matched 11,617 pairs of patients with diabetes and no CKD at baseline. SGLT2 inhibitor use was associated with lower risks of incident CKD (aHR 0.86; 95% CI 0.83–0.89), macroalbuminuria, acute kidney injury, cardiovascular events, and death. Although the dialysis estimate was lower, its CI crossed 1 (0.46; 0.20–1.06) and should not be described as a statistically significant reduction.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
